研究单位：[1]Ruijin Hospital[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[3]Sichuan Cancer Hospital & Institute,Chengdu,China[4]Changhai Hospital,Shanghai,China[5]Yantai Yuhuangding Hospital,Yantai,China
研究目的：
This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
